ADME / Tox

Join DDW for this exclusive free event, Are in vitro metabolism and drug-drug interaction studies critical for an investigational new drug application? which is supported by BioIVT. Expert Dr Andrew G Taylor, PhD, ADME Technical Sales Specialist, BioIVT, will present this event which will take place on 5 September 2023, 4PM BST, 11AM EST, 5PM CEST, 8AM PDT. […]

Join DDW for this exclusive free event, Are in vitro metabolism and drug-drug interaction studies critical for an investigational new drug application? which is supported by BioIVT. Expert Dr Andrew G Taylor, PhD, ADME Technical Sales Specialist, BioIVT, will present this event which will take place on 5 September 2023, 4PM BST, 11AM EST, 5PM CEST, 8AM PDT. […]

Join DDW for this exclusive free event, Are in vitro metabolism and drug-drug interaction studies critical for an investigational new drug application? which is supported by BioIVT. Expert Dr Andrew G Taylor, PhD, ADME Technical Sales Specialist, BioIVT, will present this event which will take place on 5 September 2023, 4PM BST, 11AM EST, 5PM CEST, 8AM PDT. […]

Join DDW for this exclusive free event, Are in vitro metabolism and drug-drug interaction studies critical for an investigational new drug application? which is supported by BioIVT. Expert Dr Andrew G Taylor, PhD, ADME Technical Sales Specialist, BioIVT, will present this event which will take place on 5 September 2023, 4PM BST, 11AM EST, 5PM CEST, 8AM PDT. […]

In vitro ADME and drug-drug interaction (DDI) investigations are early activities in the drug development process that are critical for framing downstream decision making. Understanding the ADME properties and DDI risks of your compound helps you avoid unnecessary clinical studies, costs, delays and more. This webinar will provide insights at a high-level related to regulatory […]

The 3D cell culture company, CN Bio, has launched Drug Metabolism and Safety Toxicity Testing Services. Liver toxicity is a principal safety concern during drug discovery and development, with the potential to terminate expensive clinical trials already underway. The new services will incorporate the company’s advanced Liver-on-Chip technology and expertise in the field to enable […]

By Andrii Lozoniuk Volume 21 Issue 2 – Spring 2020 Gathering compound solubility data is a key step during drug discovery that helps ensure cost-effective screening, yet it is a long process and is often underestimated in terms of difficulty. Global sharing of such data can help pharmaceutical companies minimise unnecessary expenditures in terms of […]

Getting a handle on liquids: automation solutions for drug discovery By Helen Stewart-Miller and Thomas Hope The accurate and precise measurement of liquids and the transport of exact volumes between vessels, or from one instrument to another, are processes that constitute the very essence of research. However, while this simple requirement for the meticulous handling […]

Using Live-Cell Imaging Systems to Transform Perspectives in Drug Discovery By Helen Stewart-Miller and Dr Kate Tointon Live-cell imaging has transformed the study of cell behaviour and function. The technique allows researchers to monitor internal cell structures, interactions and processes in real-time, and over time. In drug discovery, understanding the dynamic processes of cells provides […]

How Artificial Intelligence is Transforming Drug Design By Dr Mark Roberts and Dr Sam Genway AI could create a streamlined, automated approach to drug discovery, trawling vast datasets to identify targets, find candidate molecules and predict synthesis routes. Getting there will require significant vision, but we are already seeing exciting examples of AI helping direct […]

Optimising Phenotypic Screening – Single-cell analysis versus 3D multicell analysis By Dr Richard M. Eglen In light of the high failure rate of compounds when they are subjected to clinical testing, we are seeing a renaissance in phenotypic screening in drug discovery. However, most phenotypic screening is based on the use of cellular assays and […]

Systems Pharmacology: When multi-targeting is advantageous By Dr Kirkwood A. Pritchard Jr, Dr Dustin P. Martin and Dr Stephen Naylor The safety and efficacy of therapeutic drugs still requires improvement. In part this is due to the promiscuity of individual drugs, which on average can interact with an estimated 6-28 other off-target moieties. However, the […]

Hepatic Model Helps to Predict Clinically-Relevant Botanical-Drug Interactions By Dr Amy L. Roe and Dr Jonathan P. Jackson Use of botanical-based dietary supplements is increasing among people of all ages and in most geographies. Most of these populations have ready access to conventional medications, with significant polypharmacy observed in older adults. The scientific literature is […]

The Future Of Drug Discovery – Cutting-edge technologies meet traditional paradigms in assay development By Dr Roger Bosse With more than 1,500 drugs approved by the Food and Drug Administration (FDA) on the market, the easiest disease targets are already covered (1). Today’s scientists are challenged to find new compounds, acting alone or in combination, […]

By Dr Simon Moore, Dr Kirsty Harper & Dr Sylwia Marshall The impact and effective routes of non-clinical safety assessment of inhaled biopharmaceuticals. With the rapid generation of biological screening data and the potential for innovative selection of compounds for screening, the importance of multivendor collaborations together with improvements in automation has never been greater […]

Breaking Down Silos in Drug Development – Why interdisciplinary integration is fundamental for pharma’s future By Dr Paul Overton In this article, we consider the symptoms and consequences of a silo culture in drug development, and look at how interdisciplinary integration should be at the heart of every pharma business model. A silo mentality is […]